Genprex Inc

As of June 30, 2026, Genprex Inc carries a market capitalization of 5.66M, placing it among publicly traded companies globally. Its enterprise value stands at -9.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Genprex Inc's next confirmed earnings release is scheduled for September 2, 2026.

As of June 30, 2026, Genprex Inc has 504,935.00 shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Genprex Inc maintains a current ratio of 6.77, meaning it holds 6.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Genprex Inc posted a negative return on equity (ROE) of -203.86, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -157.40, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 13.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Genprex Inc's stock has declined approximately 99.05% over the past 52 weeks. The 50-day moving average sits at 3.30, while the 200-day moving average is 22.49.

Over the twelve months ended June 30, 2026, Genprex Inc generated - - in revenue and converted that into -16.50M in net income, yielding earnings per share of -67.80. EBITDA reached -15.84M, while operating income came in at -15.84M.

These figures are as of June 30, 2026. Total book value stands at 14.80M, with working capital of 13.50M providing operational flexibility.

Genprex Inc produced -15.56M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -570.24: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -518.62, meaning Genprex Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Genprex Inc's most recent stock split took place on July 17, 2026 with a 22:1 split ratio.

As of June 30, 2026, Genprex Inc has an Altman Z-Score of -15.35, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.